Piramal Pharma Cuts China Raw Material Dependence to Single Digits
Piramal Pharma says its reliance on Chinese raw materials is now in single digits, a risk-management step, and lifts FY27 revenue growth guidance to 19-20%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Piramal Pharma has lowered its reliance on raw materials from China to single-digit levels, chairperson Nandini Piramal told the ET newspaper in an interview, as reported by Moody’s. The figure refers to China’s share of the company’s consolidated procurement spending, and she did not disclose the share it held before.
Piramal described the shift as a way to manage supply-chain risk rather than a source of commercial advantage. The company also relies on plants in India, the UK and the US. Second-quarter revenue rose 28% year on year to 2,617 crore rupees, and the company raised its FY27 revenue growth guidance to 19-20%.
why it matters
For investors, this points to Indian drugmakers steadily moving away from Chinese suppliers amid geopolitical tensions. Diversification is costly in an inflationary environment, so the margin impact will depend on how quickly replacement suppliers can be secured.
tags
instruments
sources
- 'Piramal Pharma has Cut China Raw Material Dependence to Single Digits' — Moody's, 29 October 2026 at 04:12 UTC
- 'Piramal Pharma Has Cut China Raw Material Dependence to Single Digit' — Moody's, 29 October 2026 at 04:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗